Cresco Labs Establishes At-the-Market Offering

Executive Summary

• Cresco Labs entered into an equity distribution agreement with Haywood Securities to sell up to US$100 million (C$140 million) of subordinate voting shares on a at‑the‑market (“ATM”) basis.
• Proceeds from any sales under the ATM program will be used principally for general corporate purposes, including potential future acquisitions and balance‑sheet strengthening.
• The ATM program is being conducted pursuant to a prospectus supplement dated January 29 2026 and the company’s short‑form base shelf prospectus dated October 3 2025.

Key Details

• Agreement: Equity Distribution Agreement with Haywood Securities Inc. allowing optional sales of up to US$100 million (C$140 million) of subordinate voting shares.
• Share Type: Subordinate Voting Shares (non‑voting or limited‑voting equity).
• Pricing: Shares will be sold at prevailing market prices at the time of each transaction; pricing may vary between purchasers and over time.
• Volume & Timing: Determined at the sole discretion of Cresco Labs’ management; no shares have been sold under the agreement to date.
• Use of Proceeds: Primarily for general corporate purposes, including potential future acquisitions, balance‑sheet strengthening, and other strategic initiatives.
• Regulatory Filings: Prospectus supplement dated January 29 2026 and base shelf prospectus dated October 3 2025 filed with Canadian securities regulators; documents available on SEDAR+.
• Legal Disclaimer: Offering not registered under U.S. securities laws; sales will be made only through the Canadian Securities Exchange in compliance with applicable regulations.

Notable Quotes

“Establishing this ATM program provides us with another flexible tool to support our strategic objectives as the industry continues to mature and federal reform progresses… Use of the program would be considered opportunistically, with a focus on market conditions, our equity valuation, and the ability to deploy capital into accretive opportunities that enhance profitability and strengthen our balance sheet,” – Charlie Bachtell, CEO, Cresco Labs.